AMT Obtains License to Amgen's GDNF Gene to Develop Treatment for Parkinson's Disease with AMT's Proprietary Gene Therapy Platfo
AMSTERDAM, The Netherlands, September 18 /PRNewswire/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it obtained a license…